Altshuler Shaham Ltd Invests $482,000 in Sanofi (NASDAQ:SNY)

Altshuler Shaham Ltd bought a new stake in Sanofi (NASDAQ:SNY) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 10,000 shares of the company’s stock, valued at approximately $482,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. NewEdge Advisors LLC raised its holdings in shares of Sanofi by 19.3% in the 4th quarter. NewEdge Advisors LLC now owns 36,796 shares of the company’s stock worth $1,775,000 after purchasing an additional 5,958 shares during the period. Evergreen Capital Management LLC raised its holdings in Sanofi by 14.6% in the fourth quarter. Evergreen Capital Management LLC now owns 17,099 shares of the company’s stock valued at $825,000 after buying an additional 2,181 shares during the period. Guggenheim Capital LLC purchased a new position in Sanofi in the fourth quarter valued at approximately $295,000. Causeway Capital Management LLC grew its stake in Sanofi by 38.8% during the fourth quarter. Causeway Capital Management LLC now owns 690,436 shares of the company’s stock worth $33,300,000 after buying an additional 192,954 shares during the period. Finally, CreativeOne Wealth LLC acquired a new stake in shares of Sanofi in the fourth quarter worth $423,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Analysts Set New Price Targets

SNY has been the subject of a number of research reports. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. BNP Paribas started coverage on Sanofi in a report on Tuesday. They set an “outperform” rating and a $65.00 target price on the stock. The Goldman Sachs Group assumed coverage on Sanofi in a report on Friday, March 21st. They issued a “neutral” rating and a $65.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $63.33.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $50.56 on Thursday. The business has a 50 day moving average price of $54.83 and a two-hundred day moving average price of $52.28. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $60.12. The firm has a market cap of $127.73 billion, a PE ratio of 20.31, a price-to-earnings-growth ratio of 1.01 and a beta of 0.57. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Sell-side analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.